



RECEIVED

NOV 20 2002

TECH CENTER 1600/2900

1614

S  
VE  
12.13

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Robert F. Hofmann, et al.

Serial No.: 09/822,773

Filed: March 30, 2001

Art Unit: 1614

Examiner: John D. Pak

For: **USE OF TARGETED OXIDATIVE THERAPEUTIC FORMULATION IN  
ARTERIOSCLEROSIS**

Commissioner for Patents  
Box: NON-FEE AMENDMENT  
Washington, D. C. 20231

Sir:

**CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.8**

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on November 11, 2002.

*M. Alford*  
M. Alford

**RESPONSE TO RESTRICTION REQUIREMENT**

Applicants wish to thank the Examiner for his advice regarding the current election of species, which was given on November 7, 2002 by telephone.

In response to the Examiner's communication mailed October 21, 2002, Applicants hereby elect, without traverse, to prosecute in this application the following disclosed species:

- (i) reaction product from oxidation of alkene, wherein the alkene is geranylgeraniol;
- (ii) penetrating solvent such as DMSO;
- (iii) dye containing chelated divalent or trivalent metal such as porphyrin; and
- (iv) aromatic redox compound such as benzoquinone.

Applicants submit that the election of species (i) is now complete and respectfully request that the application be taken up for further examination.

Respectfully submitted,

T. Ling Chwang  
T. Ling Chwang  
Reg. No. 33,590  
Jackson Walker L.L.P.  
2435 North Central Expressway, Suite 600  
Richardson, Texas 75080  
Tel: (972) 744-2919  
Fax: (972) 744-2909

Nov. 11, 2002  
Date